Specialty Pharmacy

Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses developments in contracting that specialty pharmacies need to be aware of.

Attacking protein could potentially treat a number of conditions, including the Ebola virus, brain cancer, and hepatitis.

Improper vaccine storage is surprisingly common and may be one cause of the rising incidence of vaccine-preventable diseases across the United States.

Data published in The Lancet Infectious Diseases on Jan. 8 shows that some contraceptives for women may increase the risk of contracting HIV. This information comes from researchers from the University of California Berkeley, who analyzed 12 studies.

Study finds many patients not receiving radiation treatment.

American Cancer Society reports significant progress in death rates.

Supreme Court to decide legality of offering subsidies to low- and moderate-income people who purchase coverage through federally run health insurance marketplaces.

Most patients treated with high-dose immunosuppressive therapy and who had their own hematopoietic stem cells transplanted experienced sustained remission after 3 years.

While some researchers have associated human papillomavirus vaccination with an increased risk for multiple sclerosis, a new study found no such link between the vaccine and the development of demyelinating disease.

Low vitamin D levels may prolong the duration of mechanical ventilation in critically ill surgical patients.

Targeted therapy found to shrink tumor growth.

Side effects found to make it harder for patients to concentrate.

Hepatitis B vaccination reduces incidence of primary liver cancer by 84% later in life, study finds.

Pharmaceutical manufacturing in the United States inched a step closer to a historic milestone today when the FDA Oncologic Drugs Advisory Committee recommended approval of the investigational biosimilar, filgrastim.

Specialty pharmacies offer a unique distribution model that, unlike more restrictive product distribution models, enables manufacturers to track product use in real time without having a substantial negative effect on patient access.

The FDA today granted orphan drug designation to an experimental drug that treats several types of blood cancers.

Research may lead to targeted therapeutic approach.

Company's comprehensive drug portfolio further expands with addition of 2 leading products.

Thomas Morrow, MD, chief medical officer at Next IT, discusses the various difficulties faced by patients when they begin a specialty therapy regimen.

Manufacturing practice requirements leave pharmaceutical manufacturers vulnerable.

Women who take bisphosphonates, which are commonly used to treat osteoporosis and other bone conditions, have about half the risk of developing endometrial cancer as women who do not use the drugs. This study supports other research showing that bisphosphonates may have an anticancer effect.

Researchers seek better targets for blocking events that lead to drug resistance.

Pharmacists with the shortest length of service and no specialties less likely to cooperate with physicians.

Study finds disease leads to worse low and high frequency hearing.

Cystic fibrosis patients frequently infected with strains of life-threatening virus.

Increase found in the number of eligible hepatitis C patients being treated following approval of new treatments.

Drug found to be as effective as current treatment without serious side effects.

Investigational drugs shut down critical genes and cancer cells responsible for tumor growth.

Teva's Granix Injection has been approved by the FDA for self-administration by patients and caregivers.

Raulo Frear, PharmD, general manager of OmedaRx, discusses the high initial cost of hepatitis C drugs like Sovaldi compared with the long term cost of treating the disease.